Dr Paul Moore | Vice President, Cell Biology & Immunology
Macro Genics Inc

Dr Paul Moore, Vice President, Cell Biology & Immunology, Macro Genics Inc

Over 20 years of experience working in biotech, coordinating efforts focused on the discovery and development of novel biologic based therapies. Began biotechnology career at Human Genome Sciences, where directed genomic-based target discovery programs and the preclinical development of various protein and mAb-based therapeutics for the treatment of cancer, metabolic, and autoimmune diseases. Notably these efforts led to the discovery of BLyS as a B-cell survival factor providing the basis for the development of Benlysta for the treatment for lupus. At MacroGenics, leads a research group dedicated to the discovery, preclinical development and clinical translational biology of antibody-based therapeutics including Fc-optimized mAbs and bispecifics for cancer or autoimmune disease through harnessing of the host immune system. Obtained PhD from University of Glasgow and performed post-doctoral work at the Roche Institute of Molecular Biology; co-authored over 70 peer-reviewed manuscripts and 40 issued US patents.


Day 2 Oct 11th Immune Profiling @ 11:40

Advanced development of innovative immunotherapeutics: in combination and exploiting the DART platform

  • Overview of current progress, lessons learned, and future prospects for the combination immunotherapy of cancer
  • Discussing how application of the DART platform leads to enhanced checkpoint blockade
  • Mechanisms by which anti-tumour immune responses can be evoked when employing the novel DART platform

back to speakers